The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical
Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients.
 
Yosuke Togashi
No Relationships to Disclose
 
Takahiro Kamada
No Relationships to Disclose
 
Akinori Sasaki
No Relationships to Disclose
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma
Other Relationship - Abbott Japan; Chugai Pharma
 
Shota Fukuoka
No Relationships to Disclose
 
Yasuko Tada
No Relationships to Disclose
 
Akihito Kawazoe
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Research Funding - Daiichi Sankyo; Kyowa Hakko Kirin; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo